Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Ulcerative Colitis Drugs Market $13.7 Billion by 2031

The global market for ulcerative colitis drugs predicted to reach $13.7 billion by 2031, growing steadily at a CAGR of 6.0% over the forecast period, mostly driven by the increasing prevalence of ulcerative colitis, and introduction of several new therapies, mainly the IL-23 and JAK inhibitors in the recent years.

  • In the recent years, biologic therapies, including tumor necrosis factor (TNF) antagonists and the anti-α4β7 antibody vedolizumab, have improved the management of UC compared to conventional therapeutics. Newer treatment options have launched recently or are in the late stages of development, and may prove to be more effective than existing therapies.
    • In addition, the emerging therapies for UC are generally for moderately to severely active UC. These therapies are either orally delivered small molecules or injectable biologics and offer a new mechanistic approach or have better selectivity profiles than currently exploited therapeutic strategies.
Global Ulcerative Colitis Drugs Market

Inflammatory bowel disease (IBD) represents a group of intestinal disorders, ulcerative colitis (UC) and Crohn’s disease (CD) that cause prolonged inflammation of the digestive tract. Both UC and CD are chronic conditions that involve inflammation of the GI tract, although patients may experience periodic episodes of remission and relapse. The major difference between the two conditions is the area of the GI tract affected; UC affects the colon only, while CD can affect all of the digestive system.

  • The burden of IBD is rising substantially worldwide. The incidence and prevalence of UC is increasing worldwide. The incidence of UC is much lower in developing jurisdictions than in developed jurisdictions, but emerging data reveal an increase in the incidence in developing jurisdictions. Although the incidence of UC and CD is high in Western countries, it might be plateauing.

Similar to CD, UC is now considered a progressive disease owing to the risks of proximal extension, strictures, gut dysmotility, anorectal dysfunction, need for colectomy, hospitalization, colorectal cancer, disability and impaired quality of life. Given its potentially progressive and debilitating disease course, the therapeutic goals for UC have changed over the past decade, from treating symptoms to mucosal healing, with the aim of modifying the natural history of the disease and improving long-term outcomes.

  • The first-line of treatment for mild-to-moderate UC involves conventional therapies such as the oral aminosalicylates and corticosteroids, whereas tumor necrosis factor-alpha (TNF-α) inhibitors are primarily used for moderate-to-severe disease that is refractory to conventional therapies or for the first-line treatment of very severe disease.
    • The systemic corticosteroids are often required for acute UC. Parenteral infusion of cyclosporine can also be effective in treating severe UC that is refractory to corticosteroids, and can delay or prevent the need for surgery.
      • However, increased use of corticosteroids, in turn, can result in several adverse effects, including osteoporosis, depression, moon face, type 2 diabetes mellitus and cataracts.
  • For patients with moderate-to-severe UC or those who are corticosteroid-dependent, parenteral treatment options often involve TNF inhibitors including infliximab (Remicade), adalimumab (Humira) or golimumab (Simponi).
  • Similarly, the anti-integrin therapy Vedolizumab (Entyvio), a humanized monoclonal antibody is used as a second-line parenteral treatment for patients with moderate to severe UC who cannot take anti-TNF drugs because of side effects, lack of efficacy or loss of response, and as first-line therapy in patients in whom the risks of anti-TNF therapy may be increased.

The global ulcerative colitis drugs market research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2024).

The global ulcerative colitis drugs market segmentation is based on product (drug class/brand) – [conventional agents (aminosalicylates, corticosteroids), tumor necrosis factor-alpha (TNF-alpha) inhibitors – Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), alpha-4 beta-7 integrin antibody – Entyvio (vedolizumab), interleukin (IL-12/IL-23) inhibitors – Stelara (ustekinumab), Janus kinase (JAK) inhibitors – Xeljanz (tofacitinib), Jyseleca (filgotinib), monoamine oxidase (MAO) inhibitors – Zeposia (ozanimod)], pipeline analysis, and geography.

  • Based on the drug classes, the anti-TNF biologics or immunosuppressants segment consisting adalimumab (Humira), and infliximab (Remicade) held the largest share of the global ulcerative colitis drugs market, followed by the anti-integrin antibody segment with vedolizumab (Entyvio).
    • Among the biologics, the TNF-alpha inhibitors (Humira and Remicade) and the calmodulin (Ca2+/CaM) inhibitor (Entyvio) are the mainstays of treatment. However, therapies such as oral JAK inhibitor (Xeljanz / Xeljanz XR) and IL-23 inhibitor (Stelara) are increasing the competition among late-stage targeted therapies.
  • It is expected that, during the forecast period, the new therapies would face intense competition from the increasing introduction of biosimilars, where the major brands, including Humira, Entyvio and Remicade loose exclusivity from 2023 onwards.
  • The availability of non-TNF biologics (Entyvio, Stelara) and the oral JAK inhibitor (Xeljanz / Xeljanz XR) will expand physicians’ treatment regimens likely to intensify the market competition in the near future. The continued generic erosion of conventional agents and the entry of less-expensive biosimilars anticipated to pose hurdles to the uptake of emerging therapies.
  • Recently, in 2021, filgotinib (Jyseleca), a novel selective JAK inhibitor, was approved for the treatment of moderate to severe UC. Another JAK inhibitor, upadacitinib (Rinvoq), is also in development for this indication.

The global market for ulcerative colitis drugs research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America region accounted for the largest share of the total US treatment market, followed by the Europe region.
    • The United States remains the dominant national market for UC therapies, mostly driven by increased diagnosis rates, the introduction of newer therapies and the increased use of biologics in patients with moderate to severe disease.
      • UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries.

In addition, the global market for ulcerative colitis drugs report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global market for ulcerative colitis treatment and profiled in this report include AbbVie, Inc., Abivax SA, Arena Pharmaceuticals, Inc., Bausch Health Companies Inc. (Salix Pharmaceuticals, Inc.), Bristol Myers Squibb Company, Cosmo Pharmaceuticals NV, Eli Lilly and Company, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson, Pfizer, Inc., Roche Holding AG, and Takeda Pharmaceutical Co., Ltd.

  • Product (Drug Class/Brand)
    • Conventional Agents
      • Aminosalicylates
      • Corticosteroids
    • Tumor Necrosis Factor-alpha (TNF-alpha) Inhibitors
      • Humira (Adalimumab)
      • Remicade (Infliximab)
      • Simponi (Golimumab)
    • Alpha-4 beta-7 Integrin Antibody
      • Entyvio (Vedolizumab)
    • Interleukin (IL-12/IL-23) Inhibitors
      • Stelara (Ustekinumab)
    • Janus Kinase (JAK) Inhibitors
      • Xeljanz (Tofacitinib)
      • Jyseleca (Filgotinib)
    • Monoamine Oxidase (MAO) Inhibitors
      • Zeposia (Ozanimod)
  • Pipeline Analysis (Phase 3)
    • JAK Inhibitors
      • Rinvoq (Upadacitinib)
    • Sphingosine 1-phosphate (S1P) Receptor Modulators
      • Etrasimod (APD334)
    • Alpha-4 beta-7 Integrin Antibody
      • Etrolizumab
    • IL-23 Inhibitors
      • Skyrizi (Risankizumab)
      • Tremfya (Guselkumab)
      • Mirikizumab (LY3074828)
    • Anti-inflammatory Agent
      • ABX464
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AbbVie, Inc.
    • Abivax SA
    • Arena Pharmaceuticals, Inc.
    • Bausch Health Companies Inc. (Salix Pharmaceuticals, Inc.)
    • Bristol Myers Squibb Company
    • Cosmo Pharmaceuticals NV
    • Eli Lilly and Company
    • Galapagos NV
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Pfizer, Inc.
    • Roche Holding AG
    • Takeda Pharmaceutical Co., Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com